Google, Meta and Isomorphic Labs invest $300M in Zuckerberg Biohub's virtual cell

Google, Meta and Isomorphic Labs back Biohub's virtual cell

Google DeepMind, Meta and Isomorphic Labs, an AI drug-discovery startup, are jointly investing $300 million in Biohub, the nonprofit biomedical research organization founded by Mark Zuckerberg and his wife, Priscilla Chan. According to The Verge, which cites Reuters for the figure, the money is one piece of a $1.8 billion initiative to create AI datasets that would let researchers "ask, predict, and answer biological questions digitally" — and, in the long run, help find new ways to prevent and manage diseases.

What a virtual cell would do

Biohub was founded in 2016 with the aim of combating disease, and its central project is a "virtual cell": a computational model of living cells detailed enough that scientists could run simulated experiments rather than physical ones. The new funding targets the raw material such a model needs — large, coordinated datasets describing how cells are built and how they behave.

Alex Rives, Biohub's head of science, said in the announcement that an accurate predictive model of biology could dramatically accelerate scientific discovery by letting researchers "perform experiments digitally." He described building a virtual cell as one of the most important challenges for the next era of science, one that will require coordinated data generation "at a national and international scale" — which, he said, is why the partners are coming together.

Public money is carrying much of the load

The corporate contribution is only part of the plan. The Verge reports that the US Department of Energy will invest more than $500 million over the next five years, while the National Institutes of Health will supply datasets, repositories and knowledge bases produced by earlier federal investment that also totals more than $500 million.

Taken together, the initiative pairs three AI-focused companies with two government agencies around a single scientific goal — a structure closer to a coordinated national research program than a typical corporate grant.

Why it matters

Two of the biggest competitors in AI — Google and Meta — plus a drug-discovery startup are funding the same nonprofit effort, alongside federal agencies. That alignment signals that virtual-cell research is being treated as infrastructure-level science, requiring data generation well beyond what any single lab or company could produce alone.

If the datasets and models materialize, the payoff could be substantial. Researchers could test hypotheses about cells in software before committing bench time, shortening the loop between an idea and a validated result and potentially speeding up the search for treatments. Drug discovery is the most obvious early beneficiary, which helps explain why Isomorphic Labs is at the table.

There are open questions, too. A complete, predictive model of a living cell does not yet exist, and the announcement describes an aspiration more than a deliverable. The reporting also leaves unclear how the resulting datasets will be governed — whether they will be open to all researchers or weighted toward the funding partners. Even so, the $1.8 billion initiative is one of the larger bets that the next leap in biology will come not from a new instrument, but from enough data to simulate life digitally.